A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Open accessThe DOI matches its Crossref record.
Abstract
Aim: Omalizumab, a humanized IgG monoclonal antibody that binds to human immunoglobulin E (IgE), interrupts the allergic cascade in asthmatic patients. The aim was to compare simultaneously drug exposure and IgE biomarker responses in Japanese and White patient populations. Methods: An instantaneous equilibrium drug–ligand binding and turnover population model was built from 202 Japanese patients. A posterior predictive evaluation for the steady‐state distributions of omalizumab and IgE was then carried out against 531 White patients. Results: The mean parameters estimated from the Japanese patients were as follows: omalizumab clearance 7.32 ± 0.153 ml h−1, IgE clearance 71.0 ± 4.68 ml h−1 and the difference between that for omalizumab and the complex 5.86 ± 0.920 ml h−1, the volume of distribution for omalizumab and IgE 5900 ± 107 ml, and that for the complex 3630 ± 223 ml, the rate of IgE production 30.3 ± 2.04 µg h−1. Half‐lives of IgG (23 days) and IgE (2.4 days) were close to previous reports. The dissociation constant for binding, 1.07 nM, was similar to in vitro values. Clearance and volume of distribution for omalizumab varied with bodyweight, whereas the clearance and rate of production of IgE were predicted accurately by baseline IgE. Overall, these covariates explained much of the interindividual variability. Conclusions: The predictiveness of the Japanese model was confirmed by Monte‐Carlo simulations for a White population, also providing evidence that the pharmacokinetics of omalizumab and IgE were similar in these two populations. Furthermore, the model enabled the estimation of not only omalizumab disposition parameters, but also the binding with and the rate of production, distribution and elimination of its target, IgE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An exception can be the elimination of the immune complexes through Fc␥R-mediated phagocytosis (26,30,31), when two or more antibodies bind simultaneously to one antigen.”
From Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 (2012) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Cited by
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
Approximations of the Target-Mediated Drug Disposition Model and Identifiability of Model Parameters
Gibiansky, L., Gibiansky, E., Kakkar, T., & Ma, P. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9102-8 · Cited by 272
Chakraborty, A., Tannenbaum, S., Rordorf, C., Lowe, P. J., Floch, D., Gram, H., & Roy, S. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599820-000000000-00000 · Cited by 199
“Rearrangement of the previous equation gives the amount of the canakinumab-IL-1b complex in the central compartment as a quadratic solution to the binding equation (equation 7):([16,25]) XC 1⁄4 KD VC þTDC þTLC ð Þ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi…”
BackgroundSelf-citationFixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Wang, D. D., Zhang, S., Zhao, H., Men, A. Y., & Parivar, K. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337512 · Cited by 192
“For omalizumab, both PK and PD models have been established.(16) Therefore, the performance of Figure 2.”
BackgroundChaparro-Riggers, J., Liang, H., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K., Casas, M. G., Boustany, L. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319764 · Cited by 171
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
Gill, K. L., Machavaram, K. K., Rose, R. H., & Chetty, M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0361-4 · Cited by 82
Metadata
- Authors
- Hayashi, N., Tsukamoto, Y., Sallas, W. M., & Lowe, P. J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2007-02-26
- Volume
- 63
- Issue
- 5
- Pages
- 548-561
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2011018995
- Cited by
- 173
- References
- 0
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.